Skip to main
  1. Stocks
  2. Artiva Biotherapeutics Inc
  3. Forecast
ARTV

ARTV Stock Forecast & Price Target

ARTV Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Artiva Biotherapeutics is viewed favorably because AlloNK is showing encouraging early efficacy in Sjögren’s disease, an underappreciated indication with significant unmet need and no currently approved therapies. With 11 patients at ~6 months, the data show a -3.5-point mean ESSPRI improvement, robust ClinESSDAI gains, and mean stimulated salivary flow rising to ~1.1 mL/min, above the normal salivation range, while safety remains favorable across a 73-patient dataset with no ICANS, CRS, or GvHD reported. These results suggest a differentiated, community-friendly profile versus CAR T and TCE approaches, supporting the case that SjD could become the company’s next P3 focus after RA.

Bears say

Artiva Biotherapeutics is facing a severe deterioration in fundamentals after discontinuing AlloNK, its lead value driver, following two patient deaths and evidence of insufficient response durability, which halted Phase II and Phase III enrollment. The decision to cut roughly 94% of its workforce and evaluate strategic alternatives underscores that the company has lost its near-term growth engine and may struggle to create value from a pipeline that remains Phase II or earlier. Despite preliminary cash of $319.1 million as of Sep. 30, 2026 and about 50 million shares outstanding, the prospect of ~$125 million in severance and termination costs, plus the need for future financing amid intense competition and no approved NK cell therapies, supports a negative outlook.

ARTV has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artiva Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

ARTV Analyst Forecast & Price Prediction

Get the latest ARTV stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ARTV

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artiva Biotherapeutics Inc (ARTV) Forecast

Analysts have given ARTV a Buy based on their latest research and market trends.

According to 5 analysts, ARTV has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artiva Biotherapeutics Inc (ARTV)


ARTV Analyst Forecast & Price Prediction

Get the latest ARTV stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ARTV

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ARTV stock data and trends